PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 85 filers reported holding PHATHOM PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $19,938,004 | -20.1% | 1,922,662 | +10.3% | 0.00% | -100.0% |
Q2 2023 | $24,950,265 | +196.8% | 1,742,337 | +48.0% | 0.00% | – |
Q1 2023 | $8,407,329 | -30.4% | 1,177,497 | +9.4% | 0.00% | – |
Q4 2022 | $12,079,508 | +12.4% | 1,076,605 | +11.0% | 0.00% | – |
Q3 2022 | $10,745,000 | -32.5% | 969,754 | -48.6% | 0.00% | – |
Q2 2022 | $15,909,000 | -39.8% | 1,884,852 | -3.0% | 0.00% | -100.0% |
Q1 2022 | $26,441,000 | -30.3% | 1,942,701 | +0.8% | 0.00% | 0.0% |
Q4 2021 | $37,921,000 | -34.9% | 1,927,844 | +6.3% | 0.00% | 0.0% |
Q3 2021 | $58,218,000 | +10.3% | 1,813,651 | +16.3% | 0.00% | 0.0% |
Q2 2021 | $52,783,000 | -5.0% | 1,559,289 | +5.4% | 0.00% | -50.0% |
Q1 2021 | $55,573,000 | +16.1% | 1,479,592 | +2.7% | 0.00% | +100.0% |
Q4 2020 | $47,868,000 | +75.8% | 1,440,937 | +94.1% | 0.00% | 0.0% |
Q3 2020 | $27,222,000 | +18.3% | 742,349 | +6.2% | 0.00% | 0.0% |
Q2 2020 | $23,008,000 | +333.6% | 699,119 | +240.2% | 0.00% | – |
Q1 2020 | $5,306,000 | -17.3% | 205,512 | -0.2% | 0.00% | – |
Q4 2019 | $6,415,000 | – | 205,995 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Medicxi Ventures Management (Jersey) Ltd | 4,901,358 | $41,368,000 | 8.59% |
Frazier Life Sciences Management, L.P. | 5,827,415 | $49,183,000 | 4.64% |
Abingworth LLP | 1,435,106 | $12,112,000 | 3.88% |
Penn Mutual Asset Management | 86,940 | $734,000 | 0.99% |
683 Capital Management, LLC | 1,440,000 | $12,153,000 | 0.86% |
Western Standard LLC | 109,055 | $920,000 | 0.70% |
MPM BioImpact LLC | 193,326 | $1,632,000 | 0.45% |
Newtyn Management, LLC | 255,767 | $2,159,000 | 0.41% |
StepStone Group LP | 422,085 | $3,562,000 | 0.38% |
Avidity Partners Management LP | 1,919,800 | $16,203,000 | 0.37% |